Initially, we assessed the effects of inhibiting GSK-3 activity in normal breast epithelial cells (MCF10A) using SB415286, a highly specific, small molecule inhibitor of GSK-3 (Coghlan et al., 2000
). The ability of SB415286 to inhibit GSK-3 activity was evidenced by the increased levels of cyclin D1, a protein subject to GSK-3–dependent proteolysis (Diehl et al., 1998
), in SB415286-treated MCF10A cells, relative to those treated with DMSO ( A). Inhibiting GSK-3 activity also disrupted the epithelial morphology of these cells, as evidenced by the loss of cell–cell contacts ( A).
Figure 1. GSK-3 maintains the epithelial phenotype. (A) MCF10A cells were incubated with either DMSO or 25 μM SB415286 (Biosource International) in 0.5% FBS-containing medium. Cell morphology was assessed after 72 h by phase contrast microscopy. Expression (more ...)
Loss of E-cadherin and expression of mesenchymal proteins are defining steps in the EMT. Based on our observation that inhibition of GSK-3 activity reduced cell–cell contacts in MCF10A epithelial cells, we hypothesized that GSK-3 may be a regulator of E-cadherin expression and an inhibitor of the EMT. Supporting these hypotheses, the treatment of MCF10A cells with SB415286 reduced the expression of total cellular E-cadherin protein significantly and induced the expression of the mesenchymal protein vimentin ( A) without influencing cell viability (not depicted). Together, these data indicate that epithelial cells in which GSK-3 activity has been inhibited manifest changes characteristic of an EMT.
The effects of GSK-3 inhibition can be generalized to other epithelial cells, as demonstrated by the significantly reduced levels of E-cadherin protein in HaCaT skin cells that had been incubated with the GSK-3 inhibitor ( B). This treatment also increased cyclin D1 expression, indicating the efficacy of SB415286 in HaCaT cells ( B). GSK-3 inhibition also reduced the levels of E-cadherin mRNA in GSK-3 inhibitor–treated HaCaT and MCF10A cells, relative to controls ( C). We implemented a small interfering RNA (siRNA) strategy to reduce expression of both the α and β isoforms of GSK-3 in MCF10A cells. Cells were transfected with a pool of eight siRNAs, targeting unique regions of GSK-3α and GSK-3β genes, or with a pool of nonspecific sequences ( D, Scr). Relative to the control pool, the GSK-3α and GSK-3β siRNA pool significantly decreased expression of GSK-3α and GSK-3β proteins ( D). Similar to the effect of the GSK-3 inhibitor, GSK-3–specific siRNAs markedly reduced E-cadherin mRNA ( D).
We next sought to determine the mechanism by which GSK-3 regulates E-cadherin expression. Snail, a member of the zinc finger family of transcriptional repressors, is an established suppressor of E-cadherin transcription, and its activity is an important determinant of the EMT, in the contexts of both mesoderm development (Carver et al., 2001
) and tumor progression (Batlle et al., 2000
; Cano et al., 2000
). Snail is absent in epithelial cells but expressed in tumors, and its expression has been shown to correlate inversely with tumor grade (Blanco et al., 2002
). We investigated whether GSK-3 regulates E-cadherin expression by repressing Snail expression. Inhibition of GSK-3 activity in either MCF10A or HaCaT cells significantly increased Snail mRNA levels ( A). Snail mRNA levels were also elevated in epithelial cells transfected with GSK-3–specific siRNAs ( A). As evidence that GSK-3 inhibition alters Snail transcription, we observed increased activity of a Snail promoter–driven reporter gene in HaCaT cells treated with SB415286, relative to that measured in DMSO-treated cells ( B). Increased levels of Snail protein were also detected in cells treated with the GSK-3 inhibitor ( C).
Figure 2. GSK-3 inhibits Snail transcription in epithelial cells. (A) MCF10A and HaCaT cells were either incubated with 25 μM of the GSK-3 inhibitor SB415286 or with DMSO in 0.5% FBS-containing medium. Alternatively, these cells were transfected with GSK-3α– (more ...)
Because of our recent finding that NFκB drives Snail expression (Barbera et al., 2004
), we explored whether GSK-3 inhibits Snail transcription by repressing NFκB activity. Indeed, inhibition of GSK-3 activity in HaCaT cells stimulated NFκB-dependent reporter gene expression ( A). In addition, we observed significantly decreased levels of IκB, an inhibitor of NFκB, in SB415286-treated MCF10A cells ( B). Finally, an NFκB inhibitor (SN50) suppressed the ability of SB415286 to induce Snail expression ( C). Together, these data indicate that the NFκB pathway is inhibited by GSK-3 in epithelial cells, which results in the silencing of Snail expression.
Figure 3. GSK-3 inhibits NFκB, an activator of Snail transcription. (A) HaCaT cells were transfected transiently with a luciferase construct driven by NFκB binding sites in addition to a control renilla luciferase reporter gene. These transfectants (more ...)
The data presented here indicate that GSK-3, a kinase that is active in resting epithelial cells (Papkoff and Aikawa, 1998
; Murray et al., 1999
), is a critical determinant of epithelial structure and a suppressor of the EMT. This finding implies that epithelial cells must sustain activation of a specific kinase to prevent an EMT, a mechanism distinct from that suggested by previous studies, which have shown that activation of kinases such as Akt (Grille et al., 2003
) and ILK (Oloumi et al., 2004
) can promote an EMT. An important implication of our findings is that endogenous suppressors of GSK-3, such as Wnt and PI3-kinase, which are frequently activated in carcinoma cells (Woodgett, 2001
), may also inhibit E-cadherin transcription and promote an EMT. Our observation that inhibition of both GSK-3α and GSK-3β isoforms increased Snail expression in epithelial cells ( A), whereas inhibition of either isoform alone had no effect on Snail levels (not depicted), indicates that these isoforms may serve redundant functions in maintaining epithelial architecture. Thus, we hypothesize that GSK-3α and GSK-3β isoforms serve redundant functions in epithelial cells, and that mice deficient for both GSK-3α and GSK-3β expression will exhibit prominent defects in epithelial structure and function.
The identification of NFκB as a novel target of GSK-3 activity that is relevant to the EMT is of considerable interest in light of a recent report that established NFκB as a central mediator of the EMT (Huber et al., 2004
). However, this study did not define transcriptional targets of NFκB that are important for the EMT. Clearly, Snail is a prime candidate for such an NFκB target.
Although we identify NFκB and Snail as novel targets of GSK-3 activity that are relevant to the EMT, it is likely that multiple GSK-3 substrates participate in the regulation of epithelial structure. Upon its phosphorylation by GSK-3, β-catenin, a protein that has been implicated in mesenchymal transitions (Kim et al., 2002
; Liebner et al., 2004
), is degraded by the proteosome pathway, resulting in its inability to stimulate TCF/LEF transcription factors (Beals et al., 1997
). TCF/LEF can induce the expression of genes that influence the EMT, such as vimentin (Gilles et al., 2003
), the levels of which are elevated in epithelial cells treated with the GSK-3 inhibitor ( A). Thus, multiple signaling pathways that control the EMT are likely to be regulated by GSK-3, substantiating our hypothesis that this kinase is a central regulator of epithelial structure and function.
It is important to mention that Snail was recently identified as a direct target of GSK-3 kinase activity (Zhou et al., 2004
), and the two GSK-3 phosphorylation sites identified were shown to influence Snail protein stability and localization in tumor cells. In contrast, the present study indicates that, in epithelial cells, GSK-3 impedes Snail transcription. The data presented here provide one explanation for why epithelial cells, which are characterized by high basal GSK-3 activity (Papkoff and Aikawa, 1998
; Murray et al., 1999
), express negligible levels of Snail mRNA (; Domínguez et al., 2003
; Peinado et al., 2003
). The combined abilities of GSK-3 to block Snail transcription, promote Snail degradation, and prevent Snail nuclear localization indicate that this kinase plays a central role in regulating Snail expression. Future studies addressing the importance of posttranslational control of Snail by GSK-3 in epithelial cells will be crucial for establishing the relevance of this mode of regulation for the EMT.
GSK-3 is a central target for the development of therapeutics because it has been implicated in numerous pathologies, including diabetes and neurologic disorders (Woodgett, 2001
). Our findings suggest that this kinase is active in epithelial cells for a very important reason, namely to prevent the acquisition of a mesenchymal phenotype. Because reduced E-cadherin expression has been reported to be characteristic of some malignant tumors (Bringuier et al., 1993
; Hirohashi, 1998
; Kowalski et al., 2003
), our findings indicate that inhibition of GSK-3, an enzyme that maintains E-cadherin expression, will not prove to be a reasonable therapeutic strategy because it has the potential to alter epithelial function significantly.